In 2014, to eke out a little more time with patent protection for Lantus in the United States, Sanofi sued, claiming that the Lilly product violated four patents, which triggered the automatic thirty-month Hatch-Waxman “waiting period.” “So the biggest thing that will affect patients with type 1 diabetes here is being decided legally not medically,”
